COMPANY

Orphagen Pharmaceuticals, Inc.

HQ: San Diego, CA source · orphagen.com ↗ · West Coast

Keywords: small molecule oncology cancer

Location: San Diego, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

31NIH grants

Timeline

Jul 16, 2025 Grant Government grant — SBIR: $634,145 (annual award, as published), announced Jul 16, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗
Dec 9, 2024 Grant Government grant announced Dec 9, 2024. Source: company's own press page. source ↗

Funding

Last 2 years.

Jul 16, 2025 Government grant — SBIR: $634,145 (annual award, as published), announced Jul 16, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗
Dec 9, 2024 Government grant announced Dec 9, 2024. Source: company's own press page. source ↗

NIH awards 31

Annual award amounts. Total $11.0M.

Sep 5, 2024 NIH award 1R44DK136458-01A1 FY2024: $1,078,081 awarded for that fiscal year; activity R44 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. A novel, pleiotropic oral dru source ↗
Jun 30, 2022 NIH award 5R44CA265639-02 FY2022: $693,171 awarded for that fiscal year; activity R44 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Preclinical development of OR-449 source ↗
Jul 5, 2021 NIH award 1R44CA265639-01 FY2021: $1,306,362 awarded for that fiscal year; activity R44 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Preclinical development of OR-4 source ↗
Jul 24, 2020 NIH award 5R44HD100256-02 FY2020: $719,059 awarded for that fiscal year; activity R44 (SBIR); PI CROWE, PAUL D; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Translational feasibility of an oral, non source ↗
Aug 12, 2019 NIH award 1R44HD100256-01 FY2019: $1,093,784 awarded for that fiscal year; activity R44 (SBIR); PI CROWE, PAUL D; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Translational feasibility of an oral, n source ↗
Jul 25, 2016 NIH award 5R43HL124897-02 FY2016: $160,677 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. HLS-Small Molecule Discovery at N source ↗
Aug 18, 2015 NIH award 1R43HL124897-01A1 FY2015: $164,374 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. HLS-Small Molecule Discovery at source ↗
Jul 1, 2015 NIH award 1R43CA200076-01 FY2015: $224,954 awarded for that fiscal year; activity R43 (SBIR); PI TAO, HAIYAN; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Orphan Nuclear Receptor as Novel Drug Disco source ↗
Sep 18, 2014 NIH award 1R43DK102221-01A1 FY2014: $223,229 awarded for that fiscal year; activity R43 (SBIR); PI CROWE, PAUL D; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Small Molecule Target for Inhibition of source ↗
Jun 6, 2014 NIH award 5R43TR000976-02 FY2014: $222,161 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Pharmacological Suppression of Ro source ↗
May 28, 2013 NIH award 1R43TR000976-01A1 FY2013: $224,474 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Pharmacological Suppression of source ↗
Jul 16, 2012 NIH award 1R43CA163009-01A1 FY2012: $250,507 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Neural Stem Cell-Selective Drug source ↗
Sep 17, 2011 NIH award 1R43HD068078-01A1 FY2011: $220,839 awarded for that fiscal year; activity R43 (SBIR); PI CROWE, PAUL D; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. A Novel Target for the Treatment of End source ↗
Jun 3, 2011 NIH award 5R43CA150540-02 FY2011: $120,331 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Inhibitor of Adrenal Steroid Synt source ↗
Aug 6, 2010 NIH award 5R44MH075461-04 FY2010: $481,388 awarded for that fiscal year; activity R44 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Novel CNS Target for Sleep-Wake a source ↗
May 26, 2010 NIH award 1R43CA150540-01 FY2010: $400,027 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Inhibitor of Adrenal Steroid Synt source ↗
Nov 23, 2009 NIH award 3R44MH075461-03S1 FY2010: $204,192 awarded for that fiscal year; activity R44 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Novel CNS Target for Sleep-Wake source ↗
Sep 30, 2009 NIH award 2R44MH075461-03 FY2009: $479,791 awarded for that fiscal year; activity R44 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Novel CNS Target for Sleep-Wake a source ↗
Jun 19, 2008 NIH award 1R43DK079452-01A1 FY2008: $266,559 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Small Molecule Inhibitors of Ef source ↗
May 19, 2008 NIH award 5R43NS059219-02 FY2008: $210,190 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Feasibility Study of Novel Drug T source ↗
Sep 5, 2007 NIH award 1R43AR055427-01 FY2007: $258,166 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Small molecule target for suppres source ↗
Jun 15, 2007 NIH award 1R43NS059219-01 FY2007: $303,596 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Feasibility Study of Novel Drug T source ↗
Aug 11, 2006 NIH award 5R43MH075461-02 FY2006: $226,768 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Small Molecule Ligand Discovery f source ↗
Jun 14, 2006 NIH award 1R21NS057050-01 FY2006: $70,000 awarded for that fiscal year; activity R21 (OTHER_NIH); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Small Molecule Screen for Cir source ↗
Sep 21, 2005 NIH award 1R43MH075461-01 FY2005: $233,571 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Small Molecule Ligand Discovery f source ↗
Mar 31, 2005 NIH award 1R43DK071461-01 FY2005: $218,858 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Therapeutic Target for Atherogeni source ↗
Sep 27, 2004 NIH award 1R03NS050879-01 FY2004: $69,250 awarded for that fiscal year; activity R03 (OTHER_NIH); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Small Molecular Screen for Th source ↗
Jun 29, 2004 NIH award 5R43CA099875-02 FY2004: $249,846 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Adrenal Androgen Blockade for Met source ↗
Mar 5, 2004 NIH award 1R43AI060447-01 FY2004: $270,181 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Thymocyte Drug Target of Immune R source ↗
Aug 4, 2003 NIH award 1R43DK065426-01 FY2003: $144,158 awarded for that fiscal year; activity R43 (SBIR); PI THACHER, SCOTT MCNEAR; recipient as written: ORPHAGEN PHARMACEUTICALS, SAN DIEGO, CA. Novel Drug Target for Bile and Ch source ↗